SNDX · Syndax Pharmaceuticals, Inc. · Stock research

Current Thesis

The leg an investor was buying in July was a two-drug commercial ramp compounding into a frontline AML label expansion. Half of that has now been marked down. Q2 2026, reported 2026-08-04, delivered total revenue of $72.8M against a $79.3M consensus and EPS of $(0.55) against $(0.49) — the second consecutive quarter in which the Revuforj line came in under the street, per BofA's 2026-08-05 note. Two firms cut targets the next day. What remains to be bought is the undated half: EVOLVE-2 Phase 3 topline in newly diagnosed NPM1m/KMT2Ar AML, guided to 2H 2026 with no fixed date, plus BEAT AML and SAVE frontline datasets at unspecified medical meetings. The narrative is MATURING, and the date that marks it is 2026-08-04 — revenue still grew 92% YoY, but the ramp is no longer beating the expectations embedded at the $25 highs, and the flow that had been chasing it has reversed.

Bullish and bearish views on Syndax Pharmaceuticals, Inc.

The model's bull view on Syndax Pharmaceuticals, Inc. (SNDX), in brief: Q2 2026 total revenue $72.8M, +92% YoY: Revuforj net revenue $54.7M (+91% YoY) plus Niktimvo collaboration revenue $18.1M (2026-08-04 release). The bear view: BofA (2026-08-05) put numbers on the miss: revenue $6M below consensus, EPS $0.08 short, Revuforj $5M under expectation, and called it a repeat of the Q1 pattern. Both cases follow in full.

Bull Case

• Q2 2026 total revenue $72.8M, +92% YoY: Revuforj net revenue $54.7M (+91% YoY) plus Niktimvo collaboration revenue $18.1M (2026-08-04 release).
• Niktimvo in-market net sales $60.3M in Q2 2026, +67% YoY, co-commercialized with Incyte; Syndax books 50% of net commercial profit.
• Loss narrowing while the launch scales: net loss $49.4M in Q2 2026 versus $71.8M a year earlier.
• Cash, equivalents and investments $575.1M at 2026-06-30, including $244M net proceeds from a $250M convertible notes offering — funding that spans the 2H 2026 frontline readouts and the 2027 pipeline starts (INFERRED from the balance and the guided milestone dates).
• Seeking Alpha reported on 2026-08-04 that management frames Revuforj U.S. peak net revenue in excess of $2B; the Q2 release itself carried no peak-sales guidance.
• Both firms that cut targets on 2026-08-05 kept Buy ratings; BofA characterized the weakness as an entry point with the long-term opportunity intact. Consensus average target of ~$38.27 across 12 analysts polled by S&P Global sits far above the 2026-08-07 close of $20.40.
• Pipeline widens beyond the two commercial assets: SNDX-4321 (EGFR) IND planned Q4 2026; SNDX-62122, a next-generation menin inhibitor for myelofibrosis, IND and Phase 1 start guided to 2027.

Bear Case

• BofA (2026-08-05) put numbers on the miss: revenue $6M below consensus, EPS $0.08 short, Revuforj $5M under expectation, and called it a repeat of the Q1 pattern. The firm wrote that the menin class "has not yet met initial expectations" and described the NPM1m market as "competitive with less urgency to treat."
• Targets came down on both sides of the range on 2026-08-05: HC Wainwright $40 → $38 (Buy), BofA $29 → $26 (Buy). The gap between the $26 low and the ~$38 average is now wide enough that the covering analysts disagree about the slope, not the story.
• R&D expense rose to $68.0M in Q2 2026 from $62.2M a year earlier while the revenue line missed; SG&A was $41.5M versus $43.8M.
• The $250M convertible was raised into the strong part of the tape and sits as equity-linked supply above its conversion price. Convertible issuance typically brings arbitrage hedging that mechanically adds to borrow demand (INFERRED — no dated short-interest figure is cited here).
• The value inflection has no calendar date. Between 2026-08-04 and an unspecified 2H 2026 EVOLVE-2 topline there is no scheduled company event to reprice the name.
• The 2026-07-14 R&D Day came and went without producing a break of the $25.15 52-week high; by 2026-08-07 the close was $20.40.

Setup & Price Structure

• Last completed daily close $20.40 (2026-08-07). 52-week high $25.15, so price sits 18.9% below it. Three-month return −5.1%, RSI(14) 35.3.
• A month ago the question was whether the coil under the 52-week high would resolve upward. It did not; price has worked back down to the $20 shelf on which the June–July consolidation was built. That shelf is the last visible structure between here and the pre-breakout zone, and it has not yet been defended with a fresh base — the 2026-08-04 print is only days old on this basis.
• RSI at 35.3 is soft without being washed out, and the −5.1% three-month return against a −18.9% drawdown from the high says the high was recent and the round trip fast.
• Crowding and positioning observables, stated as observables: two same-day target cuts on 2026-08-05; a consensus average target far above spot with one covering firm ($26) now within a few points of the tape; $244M of net convert proceeds sitting on the 2026-06-30 balance sheet, raised while the stock traded in the $20s; and no earnings date inside the next 30 days, the Q2 print having already cleared on 2026-08-04.

Catalyst Calendar (next 30 days)

Nothing inside the 30-day window from 2026-08-09 carries a confirmed company date. The nearest dated and guided items:

• 2026-H2 (company guidance, no fixed date) — EVOLVE-2 Phase 3 topline, revumenib + venetoclax/azacitidine in newly diagnosed NPM1m/KMT2Ar AML unfit for intensive chemotherapy.
• 2026-H2 (medical meetings, undated) — frontline BEAT AML data (revumenib + ven/aza) and frontline SAVE and intensive-chemotherapy combination datasets.
• ~2026-11-05 (est., from the 2026-05-04 and 2026-08-04 reporting cadence) — Q3 2026 results; the third consecutive test of Revuforj against consensus.
• 2026-Q4 (company guidance) — axatilimab Phase 2 topline in cGVHD combination with ruxolitinib, and MAXPIRe Phase 2 topline in idiopathic pulmonary fibrosis.
• 2026-Q4 (company guidance) — IND submission for SNDX-4321 (EGFR inhibitor).

What Would Change Our Mind

The structural break is the loss of the June–July shelf that has so far contained the post-July decline: a weekly close below $20 removes it and leaves no defined support until the spring range. Two non-price conditions would independently break the frame. First, EVOLVE-2 topline slipping out of the 2H 2026 window — a guidance-language change at the Q3 print (~2026-11-05, est.) would date it, and it would strand the name with no catalyst until 2027. Second, a third straight quarter of Revuforj landing under consensus, which would convert BofA's "has not yet met initial expectations" from one firm's characterization into the consensus model. On the other side, a weekly close back above $25.15 on frontline data would re-establish the leg that failed in July and would argue the August drawdown was an expectations reset rather than a demand problem.

Correlation Notes

• Incyte (INCY) is the closest read-through: Incyte books Niktimvo in-market sales ($60.3M in Q2 2026) and Syndax records 50% of net commercial profit ($18.1M). Incyte's cGVHD commentary moves the Syndax line before Syndax reports it.
• Kura Oncology (KURA) and ziftomenib are the direct NPM1m menin competition; BofA's 2026-08-05 "competitive" framing is about that overlap, so relative strength between the two names is the cleanest available proxy for class share.
• Royalty Pharma's royalty-interest financing sits ahead of equity in Revuforj economics and carries a recurring P&L drag; revenue growth and equity accretion are not the same line here.
• As a loss-making, high-multiple biotech with a convertible outstanding, the name carries XBI-style beta and rate sensitivity on top of its single-franchise data risk.